バイオ医薬品CDMOの世界市場レポート2024-2030
英文タイトル: Global Biopharmaceutical CDMO Market Insights, Forecast to 2030
販売価格(消費税別)
個人版
マルチユーザー版
企業版
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=161円。
※米ドル表示価格+10%消費税。
価格表記: USDを日本円(税抜)に換算,本日の銀行送金レート: 1USD=161円。
※米ドル表示価格+10%消費税。
※ご注文方法:お問い合わせフォームまたはメールにてご連絡ください。
支払方法:「銀行振込」の場合, 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期:原則として、受注後2~4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8~10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。
概要
本報告書はバイオ医薬品CDMO市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートはバイオ医薬品CDMOの主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。
世界のバイオ医薬品CDMO市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートはバイオ医薬品CDMOのメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別にバイオ医薬品CDMO市場を分類しています。本研究に含まれる主な企業は:Lonza、Catalent、Samsung Biologics、FUJIFILM Diosynth Biotechnologies、Boehringer Ingelheim、WuXi AppTech、Recipharm、Thermo Fisher Scientific、AGC Biologics、Rentschler Biopharma、KBI Biopharma、Siegfried、Aenova Group、GenScript、ProBioGen、Northway Biotech、3P Biopharmaceuticals
地域別市場区分、地域別分析は以下の通り:
アメリカとカナダ
中国
アジア
ヨーロッパ
中東、アフリカ、ラテンアメリカ
タイプ別市場セグメント:
Cell and Gene Therapies
Antibodies
Vaccines
Other
用途別の市場セグメント:
SMBs
Large Companies
本レポートの詳細内容
世界のバイオ医薬品CDMO市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、バイオ医薬品CDMOタイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業のバイオ医薬品CDMO収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のバイオ医薬品CDMO市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、バイオ医薬品CDMO市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。
バイオ医薬品CDMOのレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。
章の概要
第1章:バイオ医薬品CDMOのレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント(製品タイプ、用途など)のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。(2019~2030)
第2章:バイオ医薬品CDMOの世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。(2019~2030)
第3章バイオ医薬品CDMO企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。(2019~2030)
第4章:各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。(2019~2024)
第5章:バイオ医薬品CDMOの各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。(2019~2030)
第6章:北米(米国、カナダ)のタイプ別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第7章:ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第8章:中国の種類別、および用途別、各セグメントの収益。(2019~2030)
第9章アジア(中国を除く)の種類別、用途別、地域別、セグメントごとの収益。(2019~2030)
第10章:中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。(2019~2030)
第11章:バイオ医薬品CDMOの主要企業の概要を提供し、製品の説明と仕様、バイオ医薬品CDMOの収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。(2019~2024)
第12章:アナリストの見解/結論
概要
Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process. The global Biopharmaceutical CDMO market is projected to grow from US$ 28160 million in 2024 to US$ 59060 million by 2030, at a Compound Annual Growth Rate (CAGR) of 13.1% during the forecast period. The core global biopharmaceutical CDMO manufacturers include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim and WuXi AppTech. The top three manufacturers account for approximately 37% of the global share. North America is the world's largest market, accounting for nearly 32% of the market share. In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share. At the same time, in terms of application, large companies are the largest application field, accounting for 58%. Report Includes This report presents an overview of global market for Biopharmaceutical CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. This report researches the key producers of Biopharmaceutical CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biopharmaceutical CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries. This report focuses on the Biopharmaceutical CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way. This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry. Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, etc. Market Segmentation By Company Lonza Catalent Samsung Biologics FUJIFILM Diosynth Biotechnologies Boehringer Ingelheim WuXi AppTech Recipharm Thermo Fisher Scientific AGC Biologics Rentschler Biopharma KBI Biopharma Siegfried Aenova Group GenScript ProBioGen Northway Biotech 3P Biopharmaceuticals Segment by Type Cell and Gene Therapies Antibodies Vaccines Other Segment by Application SMBs Large Companies By Region North America United States Canada Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Europe Germany France U.K. Italy Russia Nordic Countries Rest of Europe Latin America Mexico Brazil Rest of South America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA Chapter Outline Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term. Chapter 2: Revenue of Biopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry. Chapter 3: Detailed analysis of Biopharmaceutical CDMO companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc. Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments. Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets. Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment. Chapter 7: Europe by Type, by Application and by country, revenue for each segment. Chapter 8: China by Type, and by Application, revenue for each segment. Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment. Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment. Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biopharmaceutical CDMO revenue, gross margin, and recent development, etc. Chapter 12: Analyst's Viewpoints/Conclusions
総目録
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 Market by Application
1.3.1 Global Biopharmaceutical CDMO Market Share by Application: 2019 VS 2023 VS 2030
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biopharmaceutical CDMO Market Perspective (2019-2030)
2.2 Global Biopharmaceutical CDMO Growth Trends by Region
2.2.1 Global Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2019-2024)
2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030)
2.3 Biopharmaceutical CDMO Market Dynamics
2.3.1 Biopharmaceutical CDMO Industry Trends
2.3.2 Biopharmaceutical CDMO Market Drivers
2.3.3 Biopharmaceutical CDMO Market Challenges
2.3.4 Biopharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Biopharmaceutical CDMO by Players
3.1.1 Global Biopharmaceutical CDMO Revenue by Players (2019-2024)
3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Biopharmaceutical CDMO, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Biopharmaceutical CDMO Market Concentration Ratio
3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Revenue in 2023
3.5 Global Key Players of Biopharmaceutical CDMO Head office and Area Served
3.6 Global Key Players of Biopharmaceutical CDMO, Product and Application
3.7 Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical CDMO Breakdown Data by Type
4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2019-2024)
4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030)
5 Biopharmaceutical CDMO Breakdown Data by Application
5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2019-2024)
5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biopharmaceutical CDMO Market Size (2019-2030)
6.2 North America Biopharmaceutical CDMO Market Size by Type
6.2.1 North America Biopharmaceutical CDMO Market Size by Type (2019-2024)
6.2.2 North America Biopharmaceutical CDMO Market Size by Type (2025-2030)
6.2.3 North America Biopharmaceutical CDMO Market Share by Type (2019-2030)
6.3 North America Biopharmaceutical CDMO Market Size by Application
6.3.1 North America Biopharmaceutical CDMO Market Size by Application (2019-2024)
6.3.2 North America Biopharmaceutical CDMO Market Size by Application (2025-2030)
6.3.3 North America Biopharmaceutical CDMO Market Share by Application (2019-2030)
6.4 North America Biopharmaceutical CDMO Market Size by Country
6.4.1 North America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Biopharmaceutical CDMO Market Size by Country (2019-2024)
6.4.3 North America Biopharmaceutical CDMO Market Share by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Biopharmaceutical CDMO Market Size (2019-2030)
7.2 Europe Biopharmaceutical CDMO Market Size by Type
7.2.1 Europe Biopharmaceutical CDMO Market Size by Type (2019-2024)
7.2.2 Europe Biopharmaceutical CDMO Market Size by Type (2025-2030)
7.2.3 Europe Biopharmaceutical CDMO Market Share by Type (2019-2030)
7.3 Europe Biopharmaceutical CDMO Market Size by Application
7.3.1 Europe Biopharmaceutical CDMO Market Size by Application (2019-2024)
7.3.2 Europe Biopharmaceutical CDMO Market Size by Application (2025-2030)
7.3.3 Europe Biopharmaceutical CDMO Market Share by Application (2019-2030)
7.4 Europe Biopharmaceutical CDMO Market Size by Country
7.4.1 Europe Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Biopharmaceutical CDMO Market Size by Country (2019-2024)
7.4.3 Europe Biopharmaceutical CDMO Market Size by Country (2025-2030)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
7.4.9 Nordic Countries
8 China
8.1 China Biopharmaceutical CDMO Market Size (2019-2030)
8.2 China Biopharmaceutical CDMO Market Size by Type
8.2.1 China Biopharmaceutical CDMO Market Size by Type (2019-2024)
8.2.2 China Biopharmaceutical CDMO Market Size by Type (2025-2030)
8.2.3 China Biopharmaceutical CDMO Market Share by Type (2019-2030)
8.3 China Biopharmaceutical CDMO Market Size by Application
8.3.1 China Biopharmaceutical CDMO Market Size by Application (2019-2024)
8.3.2 China Biopharmaceutical CDMO Market Size by Application (2025-2030)
8.3.3 China Biopharmaceutical CDMO Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Biopharmaceutical CDMO Market Size (2019-2030)
9.2 Asia Biopharmaceutical CDMO Market Size by Type
9.2.1 Asia Biopharmaceutical CDMO Market Size by Type (2019-2024)
9.2.2 Asia Biopharmaceutical CDMO Market Size by Type (2025-2030)
9.2.3 Asia Biopharmaceutical CDMO Market Share by Type (2019-2030)
9.3 Asia Biopharmaceutical CDMO Market Size by Application
9.3.1 Asia Biopharmaceutical CDMO Market Size by Application (2019-2024)
9.3.2 Asia Biopharmaceutical CDMO Market Size by Application (2025-2030)
9.3.3 Asia Biopharmaceutical CDMO Market Share by Application (2019-2030)
9.4 Asia Biopharmaceutical CDMO Market Size by Region
9.4.1 Asia Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Biopharmaceutical CDMO Market Size by Region (2019-2024)
9.4.3 Asia Biopharmaceutical CDMO Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type
10.2.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application
10.3.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country
10.4.1 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Biopharmaceutical CDMO Introduction
11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Biopharmaceutical CDMO Introduction
11.2.4 Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Biopharmaceutical CDMO Introduction
11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction
11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Details
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Biopharmaceutical CDMO Introduction
11.6.4 WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.6.5 WuXi AppTech Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Biopharmaceutical CDMO Introduction
11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Introduction
11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Biopharmaceutical CDMO Introduction
11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction
11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Biopharmaceutical CDMO Introduction
11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Biopharmaceutical CDMO Introduction
11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Biopharmaceutical CDMO Introduction
11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Biopharmaceutical CDMO Introduction
11.14.4 GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Biopharmaceutical CDMO Introduction
11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Biopharmaceutical CDMO Introduction
11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction
11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
表と図のリスト
List of Tables Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030 Table 2. Key Players of Cell and Gene Therapies Table 3. Key Players of Antibodies Table 4. Key Players of Vaccines Table 5. Key Players of Other Table 6. Global Biopharmaceutical CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030 Table 7. Global Biopharmaceutical CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030 Table 8. Global Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million) Table 9. Global Biopharmaceutical CDMO Market Share by Region (2019-2024) Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million) Table 11. Global Biopharmaceutical CDMO Market Share by Region (2025-2030) Table 12. Biopharmaceutical CDMO Market Trends Table 13. Biopharmaceutical CDMO Market Drivers Table 14. Biopharmaceutical CDMO Market Challenges Table 15. Biopharmaceutical CDMO Market Restraints Table 16. Global Biopharmaceutical CDMO Revenue by Players (2019-2024) & (US$ Million) Table 17. Global Biopharmaceutical CDMO Market Share by Players (2019-2024) Table 18. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2023) Table 19. Global Biopharmaceutical CDMO Industry Ranking 2022 VS 2023 Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5 and HHI) & (2019-2024) Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served Table 22. Global Key Players of Biopharmaceutical CDMO, Product and Application Table 23. Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 26. Global Biopharmaceutical CDMO Revenue Market Share by Type (2019-2024) Table 27. Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million) Table 28. Global Biopharmaceutical CDMO Revenue Market Share by Type (2025-2030) Table 29. Global Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 30. Global Biopharmaceutical CDMO Revenue Market Share by Application (2019-2024) Table 31. Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million) Table 32. Global Biopharmaceutical CDMO Revenue Market Share by Application (2025-2030) Table 33. North America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 34. North America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million) Table 35. North America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 36. North America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million) Table 37. North America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 38. North America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million) Table 39. North America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million) Table 40. Europe Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 41. Europe Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million) Table 42. Europe Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 43. Europe Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million) Table 44. Europe Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 45. Europe Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million) Table 46. Europe Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million) Table 47. China Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 48. China Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million) Table 49. China Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 50. China Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million) Table 51. Asia Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 52. Asia Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million) Table 53. Asia Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 54. Asia Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million) Table 55. Asia Biopharmaceutical CDMO Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030 Table 56. Asia Biopharmaceutical CDMO Market Size by Region (2019-2024) & (US$ Million) Table 57. Asia Biopharmaceutical CDMO Market Size by Region (2025-2030) & (US$ Million) Table 58. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024) & (US$ Million) Table 59. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030) & (US$ Million) Table 60. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024) & (US$ Million) Table 61. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030) & (US$ Million) Table 62. Middle East, Africa, and Latin America Biopharmaceutical CDMO Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030 Table 63. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024) & (US$ Million) Table 64. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030) & (US$ Million) Table 65. Lonza Company Details Table 66. Lonza Business Overview Table 67. Lonza Biopharmaceutical CDMO Product Table 68. Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 69. Lonza Recent Development Table 70. Catalent Company Details Table 71. Catalent Business Overview Table 72. Catalent Biopharmaceutical CDMO Product Table 73. Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 74. Catalent Recent Development Table 75. Samsung Biologics Company Details Table 76. Samsung Biologics Business Overview Table 77. Samsung Biologics Biopharmaceutical CDMO Product Table 78. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 79. Samsung Biologics Recent Development Table 80. FUJIFILM Diosynth Biotechnologies Company Details Table 81. FUJIFILM Diosynth Biotechnologies Business Overview Table 82. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product Table 83. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 84. FUJIFILM Diosynth Biotechnologies Recent Development Table 85. Boehringer Ingelheim Company Details Table 86. Boehringer Ingelheim Business Overview Table 87. Boehringer Ingelheim Biopharmaceutical CDMO Product Table 88. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 89. Boehringer Ingelheim Recent Development Table 90. WuXi AppTech Company Details Table 91. WuXi AppTech Business Overview Table 92. WuXi AppTech Biopharmaceutical CDMO Product Table 93. WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 94. WuXi AppTech Recent Development Table 95. Recipharm Company Details Table 96. Recipharm Business Overview Table 97. Recipharm Biopharmaceutical CDMO Product Table 98. Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 99. Recipharm Recent Development Table 100. Thermo Fisher Scientific Company Details Table 101. Thermo Fisher Scientific Business Overview Table 102. Thermo Fisher Scientific Biopharmaceutical CDMO Product Table 103. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 104. Thermo Fisher Scientific Recent Development Table 105. AGC Biologics Company Details Table 106. AGC Biologics Business Overview Table 107. AGC Biologics Biopharmaceutical CDMO Product Table 108. AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 109. AGC Biologics Recent Development Table 110. Rentschler Biopharma Company Details Table 111. Rentschler Biopharma Business Overview Table 112. Rentschler Biopharma Biopharmaceutical CDMO Product Table 113. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 114. Rentschler Biopharma Recent Development Table 115. KBI Biopharma Company Details Table 116. KBI Biopharma Business Overview Table 117. KBI Biopharma Biopharmaceutical CDMO Product Table 118. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 119. KBI Biopharma Recent Development Table 120. Siegfried Company Details Table 121. Siegfried Business Overview Table 122. Siegfried Biopharmaceutical CDMO Product Table 123. Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 124. Siegfried Recent Development Table 125. Aenova Group Company Details Table 126. Aenova Group Business Overview Table 127. Aenova Group Biopharmaceutical CDMO Product Table 128. Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 129. Aenova Group Recent Development Table 130. GenScript Company Details Table 131. GenScript Business Overview Table 132. GenScript Biopharmaceutical CDMO Product Table 133. GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 134. GenScript Recent Development Table 135. ProBioGen Company Details Table 136. ProBioGen Business Overview Table 137. ProBioGen Biopharmaceutical CDMO Product Table 138. ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 139. ProBioGen Recent Development Table 140. Northway Biotech Company Details Table 141. Northway Biotech Business Overview Table 142. Northway Biotech Biopharmaceutical CDMO Product Table 143. Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 144. Northway Biotech Recent Development Table 145. 3P Biopharmaceuticals Company Details Table 146. 3P Biopharmaceuticals Business Overview Table 147. 3P Biopharmaceuticals Biopharmaceutical CDMO Product Table 148. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024) & (US$ Million) Table 149. 3P Biopharmaceuticals Recent Development Table 150. Research Programs/Design for This Report Table 151. Key Data Information from Secondary Sources Table 152. Key Data Information from Primary Sources List of Figures Figure 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million) Figure 2. Global Biopharmaceutical CDMO Market Share by Type: 2023 VS 2030 Figure 3. Cell and Gene Therapies Features Figure 4. Antibodies Features Figure 5. Vaccines Features Figure 6. Other Features Figure 7. Global Biopharmaceutical CDMO Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million) Figure 8. Global Biopharmaceutical CDMO Market Share by Application: 2023 VS 2030 Figure 9. SMBs Case Studies Figure 10. Large Companies Case Studies Figure 11. Biopharmaceutical CDMO Report Years Considered Figure 12. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2019-2030 Figure 13. Global Biopharmaceutical CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030 Figure 14. Global Biopharmaceutical CDMO Market Share by Region: 2023 VS 2030 Figure 15. Global Biopharmaceutical CDMO Market Share by Players in 2023 Figure 16. Global Top Biopharmaceutical CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical CDMO as of 2023) Figure 17. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2023 Figure 18. North America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 19. North America Biopharmaceutical CDMO Market Share by Type (2019-2030) Figure 20. North America Biopharmaceutical CDMO Market Share by Application (2019-2030) Figure 21. North America Biopharmaceutical CDMO Market Share by Country (2019-2030) Figure 22. United States Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 23. Canada Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 24. Europe Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 25. Europe Biopharmaceutical CDMO Market Share by Type (2019-2030) Figure 26. Europe Biopharmaceutical CDMO Market Share by Application (2019-2030) Figure 27. Europe Biopharmaceutical CDMO Market Share by Country (2019-2030) Figure 28. Germany Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 29. France Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 30. U.K. Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 31. Italy Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 32. Russia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 33. Nordic Countries Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 34. China Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 35. China Biopharmaceutical CDMO Market Share by Type (2019-2030) Figure 36. China Biopharmaceutical CDMO Market Share by Application (2019-2030) Figure 37. Asia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 38. Asia Biopharmaceutical CDMO Market Share by Type (2019-2030) Figure 39. Asia Biopharmaceutical CDMO Market Share by Application (2019-2030) Figure 40. Asia Biopharmaceutical CDMO Market Share by Region (2019-2030) Figure 41. Japan Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 42. South Korea Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 43. China Taiwan Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 44. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 45. India Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 46. Australia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 47. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 48. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030) Figure 49. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030) Figure 50. Middle East, Africa, and Latin America Biopharmaceutical CDMO Market Share by Country (2019-2030) Figure 51. Brazil Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 52. Mexico Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 53. Turkey Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 54. Saudi Arabia Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 55. Israel Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 56. GCC Countries Biopharmaceutical CDMO Market Size YoY Growth (2019-2030) & (US$ Million) Figure 57. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 58. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 59. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 60. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 61. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 62. WuXi AppTech Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 63. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 64. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 65. AGC Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 66. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 67. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 68. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 69. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 70. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 71. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 72. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 73. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Business (2019-2024) Figure 74. Bottom-up and Top-down Approaches for This Report Figure 75. Data Triangulation Figure 76. Key Executives Interviewed
01. サンプル提供
ご購入前にサンプル(英語、日本語)が提供可能。
02. カスタマイズサービス
レポートの一部をご購入可能;基本バージョンに加え、ご要望に応じたカスタム委託調査も提供可能。
03. プロフェッショナルな日本語翻訳
AI翻訳ではなく、プロフェッショナルな日本語翻訳をご提供。納期:英語は2-4営業日以内、日本語は8-10営業日以内。
04. 多言語コミュニケーション
日本語、英語、中国語、ヒンディー語、ドイツ語、韓国語、フランス語の7ヶ国語でコミュニケーションサービスをご提供。
05. お支払方法
銀行振込(納品後、ご請求書送付)。
06. アフターサービス
ご購入後、ご質問があれば、3ヵ月以内に無料でアナリストと直接的に連絡できる。
請求書払いの場合:
レポート選択
見積もり依頼
メールでのご注文
入手(英語版は2〜4営業日、日本語版は8〜10営業日)
決済(後払い)
クレジットカード決済の場合:
レポート選択
ウェブサイトでのご注文
決済
入手(英語版は2〜4営業日、日本語版は8〜10営業日)